Antioxidant

A bisphosphonic acid preparation that binds to calcium phosphate in calcified tissues addresses the need for low-concentration administration, reducing active oxygen and effectively treating blood and metabolic bone diseases with minimal side effects.

JP2024169831AInactive Publication Date: 2024-12-06FUKUSHIMA MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023086609
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Bisphosphonic acid preparations require continuous administration at high concentrations to be effective, leading to side effects such as osteonecrosis of the jaw and renal failure, necessitating a new method for use at relatively low concentrations.

Method used

A bisphosphonic acid preparation that binds to calcium phosphate in calcified tissues, reducing active oxygen levels and providing systemic medicinal effects at lower doses without affecting osteoclast function.

Benefits of technology

Reduces active oxygen in calcified tissues, blood, and lymph fluid, effectively preventing or treating blood diseases and metabolic bone diseases with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169831000009
    Figure 2024169831000009
  • Figure 2024169831000010
    Figure 2024169831000010
  • Figure 2024169831000011
    Figure 2024169831000011
Patent Text Reader

Abstract

To provide a novel method for using, at a relatively low concentration, a bisphosphonic acid preparation previously intended to be used only at a high concentration.SOLUTION: Provided is an antioxidant for binding with calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, interstitial fluid, or lymph. The antioxidant contains a compound, or a pharmaceutically acceptable salt thereof, represented by formula (I).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antioxidant, a food or beverage product and a pharmaceutical composition containing the same, and a calcium phosphate binder. [Background technology]

[0002] Bisphosphonic acids (BPs), which have two phosphate groups bound to the central carbon, are known to inhibit bone resorption by inhibiting the function of osteoclasts. To date, a wide variety of bisphosphonic acid preparations, mainly those with various side chains bound to the carbon atom mentioned above, have been developed and are widely used as drugs for various diseases associated with increased bone resorption, such as osteoporosis, hypercalcemia, Paget's disease, and tumor-induced bone destruction.

[0003] Bisphosphonic acids are broadly classified into two types depending on whether or not they contain a nitrogen atom in the side chain, and the elements contained in the side chain are halogen, nitrogen, sulfur, etc., and their structures are also diverse, such as linear, cyclic, etc. Although there are subtle differences in the mechanism of action for exerting pharmacological effects due to such differences in the side chain structure, all bisphosphonic acid preparations have in common the fact that they are first taken up by osteoclasts.

[0004] Thus, because of the need to allow each osteoclast to take up a sufficient amount of bisphosphonic acid, bisphosphonic acid preparations are assumed to be administered continuously at a high concentration. In addition, many bisphosphonic acid preparations have been problematic in that they cause serious side effects (osteonecrosis of the jaw, atypical femoral fracture, renal failure, etc.) when administered for a long period of time, although the frequency is low (Non-Patent Document 1).

[0005] [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) has been developed as a bisphosphonic acid preparation with reduced side effects (Patent Document 1). MPMBP has attracted attention as a compound that suppresses the aggravation of bacterial infection, which is believed to be one of the causes of osteonecrosis of the jaw, a side effect of bisphosphonic acid preparations, due to the antioxidant effect of the side chain, and reduces side effects. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] WO 2010 / 026701 [Non-patent literature]

[0007] [Non-Patent Document 1] Journal of the Japanese Pharmacological Society, 2019, Vol. 153, No. 1, pp. 4-10 Summary of the Invention [Problem to be solved by the invention]

[0008] Although MPMBP was useful in reducing side effects, it was necessary to administer it continuously at a high concentration in order to obtain a sufficient bone resorption inhibitory effect.

[0009] An object of the present invention is to provide a new method for using bisphosphonic acid preparations at relatively low concentrations, which have previously only been envisaged for use at high concentrations. [Means for solving the problem]

[0010] In order to solve the above problems, the present inventors have conducted intensive research and found that bone strength is improved even when bisphosphonic acid preparations are administered at a concentration that does not affect the function of osteoclasts.Furthermore, they found that the pharmacological action of bisphosphonic acid preparations is observed in blood despite the administration at such a relatively low concentration.The present invention is based on the novel finding that by administering a small amount of bisphosphonic acid preparations, the binding of the bisphosphonic acid preparation to calcified tissues is the starting point for continuous systemic pharmacological effects, and provides the following.

[0011] [1] An antioxidant for binding to calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph, the antioxidant comprising a compound represented by the following formula (I) or a pharma- ceutical acceptable salt thereof: [ka] (wherein R1 represents a hydrocarbon group or a hydrocarbon group having a substituent). [2] The antioxidant described in [1], wherein the calcified tissue is ectopic calcified tissue. [3] The antioxidant described in [2], wherein the ectopic calcified tissue is vascular tissue. [4] A food or drink comprising the antioxidant described in any one of [1] to [3]. [5] A pharmaceutical composition comprising the antioxidant according to any one of [1] to [3]. [6] The pharmaceutical composition described in [5] for preventing or treating a blood disease. [7] The pharmaceutical composition described in [6], wherein the blood disease is one or more diseases selected from the group consisting of blood clot formation, hyperlipidemia, uremia, diabetes and hypertension. [8] A composition for preventing or treating a metabolic bone disease, comprising the antioxidant according to any one of [1] to [3] in an amount such that the weekly dosage for a subject weighing 60 kg is 31 μmol or less. [9] The composition described in [8], wherein the metabolic bone disease is one or more diseases selected from the group consisting of osteoporosis, osteomalacia, rickets and osteopetrosis.

[10] A calcium phosphate binder comprising a compound represented by the following formula (II) or a pharma- ceutically acceptable salt thereof: [ka] (In the formula, R2 represents a hydrocarbon group having a substituent.)

[11] The calcium phosphate binder according to

[10] , wherein the hydrocarbon group having a substituent has a detectable label and / or a pharmacological action. Effect of the Invention

[0012] The antioxidant of the present invention can reduce the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymphatic fluid.

[0013] The composition of the present invention makes it possible to prevent or treat blood disorders and / or metabolic bone disorders.

[0014] The calcium phosphate binder of the present invention can exert a desired effect by binding to calcium phosphate. [Brief description of the drawings]

[0015] [Figure 1A-B] FIG. 1 shows the results of bone density measurements in the femur. FIG. 1A is a schematic diagram showing the sections in the femur from which the data shown in FIGS. 1B to 1E were taken. FIG. 1B is a graph showing the results of bone density measurements in the proximal region. In FIG. 1A, the vertical dashed lines indicate the boundary positions of each section, and the horizontal dashed line indicates the central axis of the femur. In FIG. 1B, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high-adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In FIG. 1B, ** indicates p<0.01. [Figure 1C] FIG. 1 shows the results of bone density measurements in the femur. FIG. 1C is a graph showing the results of bone density measurements in the proximal diaphysis. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. [Figure 1D] FIG. 1 shows the results of bone density measurements in the femur. FIG. 1D is a graph showing the results of bone density measurements in the distal diaphysis. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high-adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. [Figure 1E]FIG. 1 shows the results of bone density measurements in the femur. FIG. 1E is a graph showing the results of bone density measurements in the distal region. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. [Diagram 2] Figure 2 shows the results of measuring the storage modulus in the femur. In the figure, "Cont" shows the results for the control group, "Adenine Diet" shows the results for the high adenine diet group, of which "Veh" shows the results for the vehicle-administered group, "MPMBP 0.6" shows the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. [Figure 3A-B] FIG. 3 shows the results of measuring apatite orientation in the femur. FIG. 3A is a schematic diagram showing the sections in the femur from which the data shown in FIGS. 3B to 3E were taken. FIG. 3B is a graph showing the results of measuring apatite orientation in the proximal part. In FIG. 3A, the vertical dashed lines indicate the boundary positions of each section, the horizontal dashed lines indicate the central axis of the femur, and the black circles indicate the positions of the points where measurements were taken. In FIG. 3B, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In FIG. 3B, * indicates p<0.05, and ** indicates p<0.01. [Figure 3C]Figure 3 shows the results of measuring apatite orientation in the femur. Figure 3C is a graph showing the results of measuring apatite orientation in the proximal diaphysis. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high-adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05, and ** indicates p<0.01. [Figure 3D] FIG. 3 shows the results of measuring apatite orientation in the femur. FIG. 3D is a graph showing the results of measuring apatite orientation in the distal diaphysis. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high-adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05, and ** indicates p<0.01. [Figure 3E] FIG. 3 shows the results of measuring apatite orientation in the femur. FIG. 3E is a graph showing the results of measuring apatite orientation in the distal part. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05, and ** indicates p<0.01. [Figure 4]Figure 4 shows the results of measuring the amount of malondialdehyde in tibia samples. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. [Diagram 5] Figure 5 shows the results of measuring the amount of malondialdehyde in serum samples. In the figure, "Cont" shows the results of the control group, "Adenine Diet" shows the results of the high adenine diet group, of which "Veh" shows the results of the vehicle-administered group, "MPMBP 0.6" shows the results of the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" shows the results of the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] 1. Antioxidants 1-1. Overview The first aspect of the present invention is an antioxidant. The antioxidant of the present invention comprises a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof, and reduces the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph. The antioxidant of the present invention can be an active ingredient of foods, beverages, and pharmaceutical compositions.

[0017] 1-2.Definition "Antioxidants" (antioxidants or antioxidants) refer to substances that remove or eliminate active oxygen (superoxide anion, hydroxyl radical, hydrogen peroxide, singlet oxygen, etc.). Specifically, they include substances that can reduce active oxygen and change it into a stable molecule, thereby suppressing harmful reactions involving active oxygen. Many antioxidants are biosynthesized by animals and plants, and examples of antioxidants that are known to be derived from living organisms include vitamin C (ascorbic acid), vitamin E (tocopherol), coenzyme Q10, carotenoids, and flavonoids.

[0018] "Reactive oxygen" is a general term for highly reactive molecular species derived from oxygen molecules. In this specification, "reactive oxygen" refers to superoxide anion (O2 - ), superoxide anion radical (·O2 - ), peroxide ion (O2 2- ), hydroxyl radical (·OH), hydrogen peroxide (H2O2), singlet oxygen ( 1 These include oxygen (O2) and ozone (O3).

[0019] "Calcium phosphate" is a compound consisting of calcium ions and phosphate ions (PO3 -4 ) or diphosphate ion (P2O4 -7 It is widely found in nature as a component of hard tissues such as bones and teeth of vertebrates.

[0020] "Blood" refers to a body fluid that fills the lumen of blood vessels. In this specification, "blood" includes whole blood, plasma, and serum. The type of whole blood is not limited, and examples thereof include venous blood, arterial blood, and umbilical cord blood.

[0021] "Lymph" refers to the bodily fluid that fills the lymphatic lumen. It is mainly composed of plasma components, but when it passes through the lymphatic vessels, it is called lymph even if the same components are present in the blood.

[0022] "Tissue fluid" refers to the bodily fluid that exists between cells in tissues other than the lumen of blood vessels and the lumen of lymphatic vessels. It is also called intercellular fluid or interstitial fluid.

[0023] The term "calcified tissue" refers to tissue that has hardened due to the deposition of calcium salts. Although it may refer to soft tissue that has hardened due to the deposition of calcium salts (ectopic calcified tissue in this specification), the term "calcified tissue" in this specification broadly includes tissues in which calcium salts have been deposited, including hard tissues and ectopic calcified tissues.

[0024] "Hard tissue" refers to a hard tissue that an organism has. In vertebrates, it usually includes bones, teeth, hair, nails, cartilage, etc. In particular, "hard tissue" in this specification refers to tissue in which calcium salts are deposited and which exists in the body of a vertebrate under normal conditions. In this specification, hard tissue includes bones and teeth.

[0025] "Ectopic calcified tissue" refers to connective tissue other than bone tissue that has hardened due to the deposition of calcium salts. "Bone tissue" refers to tissue that is composed of osteoblasts, osteocytes, osteoclasts and bone matrix and constitutes bone substance.

[0026] "Blood disease" refers to a disease caused by an abnormality in the amount or function of blood cells, or an abnormality in blood coagulation factors or platelets, and is synonymous with hematological disease. Preferred blood diseases in this specification are diseases accompanied by an increase in the amount of reactive oxygen species in the blood.

[0027] The term "metabolic bone disease" refers to a disease in which bone strength is reduced due to abnormal metabolism of bone cells or bone tissue. As used herein, metabolic bone disease includes osteoporosis, osteomalacia, rickets, osteitis fibrosa cysticis, Paget's disease of bone, osteopetrosis, and the like.

[0028] "Significant" means statistically significant. Statistically significant means that there is a significant difference between the measured value of the subject and the control value when the difference between them is statistically processed. For example, the risk rate (significance level) of the obtained value is small, specifically, less than 5% (p<0.05), less than 1% (p<0.01), and less than 0.1% (p<0.001). The "p (value)" shown here indicates the probability that the test statistic will coincidentally become that value in a distribution based on the null hypothesis in a statistical test. Therefore, the smaller "p" is, the lower the probability that the test statistic will become that value, meaning that the null hypothesis is more likely to be rejected. The test method for statistical processing may be any known test method that can determine the presence or absence of significance, and is not particularly limited. For example, Student's t-test, paired Student's t-test, Welch's t-test, Wilcoxon rank sum test, analysis of variance, Tukey post-hoc test, etc. can be used, but are not particularly limited.

[0029] 1-3.Configuration The antioxidant of the present invention contains a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof as an essential component. The specific description will be given below.

[0030] [ka] (wherein R1 represents a hydrocarbon group or a hydrocarbon group having a substituent).

[0031] In the formula, the structure of R1 is not particularly limited as long as it is a hydrocarbon group or a hydrocarbon group having a substituent. The type of the hydrocarbon group is not particularly limited, and may be, for example, an aliphatic hydrocarbon group, an aromatic hydrocarbon group, or a combination thereof.

[0032] When the aliphatic hydrocarbon group is contained, it may be a saturated hydrocarbon or an unsaturated hydrocarbon. In addition, the structure of the aliphatic hydrocarbon group in this case is not particularly limited. For example, it may have a straight chain, a branched chain, a cyclic structure, or a combination of these structures. When it contains multiple aliphatic hydrocarbon groups, they may have independent degrees of unsaturation and structures.

[0033] When an aromatic hydrocarbon group is included, its structure is not particularly limited. For example, it may include one aromatic ring such as a phenyl group, may include multiple aromatic rings such as a naphthyl group, a biphenyl group, an anthracenyl group, or a phenanthryl group, or may include a ring structure other than an aromatic ring.

[0034] When the hydrocarbon group is unsaturated, the number of unsaturated bonds is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be, for example, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less. The type of unsaturated bond in the unsaturated hydrocarbon group is not particularly limited, and it can contain any number of double bonds and triple bonds.

[0035] When an isomer exists, the type of isomer is not particularly limited. For example, in the case of a cis-trans isomer, each unsaturated bond may be either a cis form or a trans form, and in the case of an optical isomer, each optical center may be either an R form or an S form.

[0036] The type of the substituent is not particularly limited. For example, the substituent may include a halogen element, a nitrogen element, an oxygen element, a sulfur element, a phosphorus element, and the like. Specifically, for example, the substituent may include a carboxy group, a ketone group, a carbonyl group, a hydroxy group, an amino group, an imino group, an amide group, a hydrazide group, an imide group, an ester group, an alkyloxy group, an alkylsulfanyl group, a nitro group, a nitroso group, a selenium derivative group, an acid halide group, a nitrile group, an aldehyde group, a hydroxy group, a hydroperoxy group, and the like. Here, the substituent also includes a case where a part of the carbon skeleton is substituted with another element. Therefore, a heterocyclic functional group is also included. The number of the substituent is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be, for example, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less.

[0037] The number of unsaturated bonds contained in the R1 portion is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be, for example, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less.

[0038] Specifically, the R1 portion can be, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a derivative thereof. For example, a compound in which the R1 portion is a methyl group is represented by formula (III) and is called [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP).

[0039] [ka]

[0040] The R1 portion can have any function as long as it does not inhibit the antioxidant activity of the compound. In this case, the function is not particularly limited, but may be, for example, a portion capable of functioning as a detectable label or a portion having a pharmacological activity. Specific examples of each will be described in detail in the fourth aspect.

[0041] The antioxidant of the present invention can contain a pharma- ceutically acceptable salt of the compound represented by formula (I) as an essential component. The type of pharma- ceutically acceptable salt of the compound represented by formula (I) is not particularly limited. For example, since the compound of formula (I) contains a phosphonic acid group, examples of the salt include base addition salts of the compound represented by formula (I). The base addition salt is formed with an inorganic base and / or an organic base. In this case, the type of inorganic base is not particularly limited. Examples of base addition salts with inorganic bases include ammonium salts, metal salts, or combinations thereof. Specific examples of metal salts include sodium salts, potassium salts, calcium salts, magnesium salts, iron, silver, zinc, copper salts, or combinations thereof. In addition, the type of organic base in the case of base addition salts with organic bases is not particularly limited. Examples of organic bases include primary, secondary, and tertiary amines, substituted amines, cyclic amines, etc. In addition, a basic ion exchange resin can be used as the organic base.

[0042] Depending on the substitution contained in the compound represented by formula (I), an acid addition salt of the compound represented by formula (I) can be used. The acid addition salt is formed with an inorganic acid and / or an organic acid. In this case, the type of inorganic acid is not particularly limited. Examples of acid addition salts with organic bases include hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates. In addition, in the case of acid addition salts with organic acids, the type of organic acid is not particularly limited. Examples of organic acids include acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and sulfosalicylic acid.

[0043] For example, as the salt of the present invention, a base addition salt of an inorganic base such as a metal salt (for example, an alkali metal salt such as a sodium salt) can be used. The salt may be anhydrous or hydrated.

[0044] 1-4.Characteristics The antioxidant of the present invention binds to calcium phosphate in calcified tissues such as bone tissue by forming a chelate structure through coordination bonding of its bisphosphonate skeleton (-CH(PO(OH)2)2) to Ca.

[0045] Whether or not a compound binds to calcium phosphate can be confirmed by any method known in the art, but it can generally be considered that a compound having a bisphosphonate skeleton will bind to calcium phosphate.

[0046] The tissue containing calcium phosphate to which the antioxidant of the present invention binds is not particularly limited, but is preferably a calcified tissue. For example, the antioxidant binds to calcium phosphate in hard tissue such as bone tissue and / or ectopic calcified tissue. The calcified tissue in the ectopic calcified tissue is not particularly limited as long as it is a soft tissue, but is, for example, vascular tissue.

[0047] The antioxidant of the present invention binds to calcium phosphate via the bisphosphonate backbone moiety and presents, on its surface, functional groups of "side chains" that exert antioxidant activity, thereby reducing the amount of active oxygen in calcified tissues, or in blood, tissue fluid, or lymph.

[0048] The type of calcified tissue on which the antioxidant of the present invention exerts its antioxidant effect is not particularly limited, but may be, for example, hard tissue such as bone tissue and / or ectopic calcified tissue. In this case, the calcified tissue in the ectopic calcified tissue is not particularly limited as long as it is a soft tissue, but may be, for example, vascular tissue. The tissue to which the antioxidant of the present invention binds and the tissue on which the antioxidant exerts its antioxidant effect may be the same or different, but usually include different tissues.

[0049] The reduction in the amount of active oxygen can be confirmed by any method. For example, the amount of active oxygen may be measured directly, or indirectly by measuring a phenomenon caused by active oxygen. Methods for directly measuring the amount of active oxygen include, for example, a luminescence method using a luminescent probe, a spin trap method, an oxygen radical absorbance capacity (ROAC) measurement method, a singlet oxygen quenching capacity (SOAC) measurement method, a color development method using a reducing agent, and a combination of these. Methods for indirectly measuring the amount of active oxygen include, for example, measurement of damage to nucleic acids, measurement of lipid peroxidation, measurement of protein oxidation or nitration, measurement of glycoxidation, measurement of antioxidants, or a combination of these.

[0050] Specific indicators of nucleic acid damage include, for example, 8-OHG, 8-OHdG, abasic sites, double-stranded breaks, BPDE adducts, or combinations thereof.

[0051] Specific indicators of lipid peroxidation include, for example, 8-OHG, 8-iso-prostaglandin, acrolein, hexanoyl lysine, isoprostane, 4-hydroxynonenal, 4-hydroxyhexenal, malondialdehyde, crotonaldehyde, 7-ketocholesterol, lipid peroxides, oxidized LDL, or combinations thereof.

[0052] Specific indicators of protein oxidation or nitration include, for example, protein carbonylation, 3-nitrotyrosine, dityrosine, dibromotyrosine, advanced glycation end products (AGEs), protein peroxides, BPDE adducts, or combinations thereof.

[0053] Specific examples of glycosides include carboxymethyllysine, glycosylated albumin, menthosidine, methylglyoxal, 3-deoxyglucosone, and combinations thereof.

[0054] Specific antioxidants include, for example, vitamin C, thiols, CoQ10 catalase, glutathione, glutathione reductase, glutathione peroxidase, myeloperoxidase, elastase, superoxide dismutase, paraoxonase, thioredoxin, thioredoxin reductase, selenoproteins, myostatin, or combinations thereof.

[0055] The method for measuring each target substance is not particularly limited, and any method known in the art can be used, such as immunoassay, ELISA, colorimetric method, and various nucleic acid detection methods.

[0056] The amount of active oxygen reduced by the use of the antioxidant of the present invention is not particularly limited. For example, the amount of active oxygen may be reduced by 20% or more, 22% or more, 25% or more, 30% or more, 35% or more, 40% or more, 41% or more, 42% or more, 45% or more, 47% or more, 48% or more, 49% or more, 50% or more, 55% or more, 60% or more, 63% or more, or 64% or more compared to the case where the antioxidant of the present invention is not used. Also, for example, the amount of active oxygen may be significantly reduced compared to the case where the antioxidant of the present invention is not used. Alternatively, for example, the amount of active oxygen may not be significantly increased when the antioxidant of the present invention is used compared to a healthy individual.

[0057] Effects The antioxidant of the present invention can exert its antioxidant effect at a dose that does not affect the function of osteoclasts.

[0058] The antioxidant of the present invention binds to calcified tissues, and the side chain is placed on the calcified tissue, and the side chain exerts a pharmacological effect on the tissues surrounding the calcified tissues, which is quite different from the conventional bisphosphonic acid preparations, which are taken up by osteoclasts and affect the osteoclasts themselves.

[0059] The antioxidant of the present invention is not only expected to be effective at a low dose, but also has the potential to provide a continuous effect even with infrequent administration. In addition, since the antioxidant of the present invention reduces oxidative stress in the blood, it is expected to have a systemic effect starting from the binding of the antioxidant of the present invention to calcified tissues.

[0060] 2. Pharmaceutical Compositions 2-1. Overview The second aspect of the present invention is a pharmaceutical composition. The pharmaceutical composition of the present invention comprises an active ingredient as an essential component, and optionally comprises a solvent and a pharma- ceutical acceptable carrier. The composition of the present invention can prevent or treat diseases or conditions such as blood diseases and / or metabolic bone diseases.

[0061] 2-2.Configuration 2-2-1. Components The components of the pharmaceutical composition of the present invention will be described. The pharmaceutical composition of the present invention contains one or more active ingredients as essential components, and contains a solvent and / or a carrier as optional components. Each component will be specifically described below.

[0062] (1) Active ingredient The pharmaceutical composition of the present invention contains the antioxidant described in the first aspect as an essential active ingredient, and may contain one or more types of antioxidants, if necessary.

[0063] The constitution of the antioxidant is not specifically described here because it has been described in detail in the first embodiment. The pharmaceutical composition of the present invention may contain one or more types of antioxidants.

[0064] The content of the active ingredient contained in the pharmaceutical composition of the present invention is not particularly limited. In general, the content varies depending on the type of active ingredient, the dosage form, and the type of the solvent and carrier, which are other components described later. Therefore, it may be appropriately determined taking into account each condition. It is sufficient that an effective amount of the active ingredient is contained in a single application amount of the pharmaceutical composition. However, when it is necessary to administer a large amount of the pharmaceutical composition to a subject to obtain the pharmacological effect of the active ingredient, it may be administered in several divided doses to reduce the burden on the subject. In this case, the amount of the active ingredient may be sufficient as long as the total amount contains an effective amount.

[0065] The term "effective amount" refers to an amount necessary for the active ingredient to function and to which it gives little or no harmful side effects to the subject to which it is applied. This effective amount may vary depending on various conditions such as the subject's information, the application route, and the number of applications. Therefore, when the pharmaceutical composition is used as a medicine, the content of the active ingredient is ultimately determined by the judgment of a doctor or pharmacist.

[0066] The composition of this embodiment is effective even when the dose of the antioxidant administered is low. The dose of the antioxidant administered in the composition of the present invention is not particularly limited, but for example, when converted into a weekly dose for a human subject weighing 60 kg, it is 1 μmol or more, 2 μmol or more, 5 μmol or more, 7 μmol or more, 9 μmol or more, 10 μmol or more, 11 μmol or more, 12 μmol or more, 13 μmol or more, 13.5 μmol or more, 14 μmol or more, 14.5 μmol or more, 15 μmol or more, 15.5 μmol or more, 15.6 μmol or more, 15.7 μmol or more, It can be 15.8 μmol or more, 15.9 μmol or more, 16 μmol or more, 16.5 μmol or more, 17 μmol or more, 17.5 μmol or more, 18 μmol or more, 18.5 μmol or more, 19 μmol or more, 19.5 μmol or more, 20 μmol or more, 21 μmol or more, 24 μmol or more, 25 μmol or more, 26 μmol or more, 27 μmol or more, 28 μmol or more, 29 μmol or more, 30 μmol or more, 30.5 μmol or more, or 31 μmol or more. Furthermore, for example, when converted into a weekly dosage for a human subject weighing 60 kg, the dosage can be 31 μmol or less, 30.5 μmol or less, 30 μmol or less, 29 μmol or less, 28 μmol or less, 27 μmol or less, 26 μmol or less, 25 μmol or less, 24 μmol or less, 21 μmol or less, 20 μmol or less, 19.5 μmol or less, 19 μmol or less, 18.5 μmol or less, 18 μmol or less, 17.5 μmol or less, 17 μmol or less, 16.5 μmol or less, 16 μmol or less, 15.9 μmol or less, 15.8 μmol or less, or 15.7 μmol or less.

[0067] In the present specification, the term "subject" refers to a subject to which the antioxidant described in the first embodiment or the pharmaceutical composition of this embodiment is applied. For example, it is a cell (including cultured cell), a tissue, an organ, or an individual. When the subject is an individual, it may be any vertebrate including human, such as birds, reptiles, mammals, primates, etc. For example, other than human, it may be a pet animal (dog, cat, rabbit, etc.), a race horse, a laboratory animal (mouse, rat, guinea pig, monkey, etc.), a livestock animal (cow, horse, sheep, goat, pig, chicken, ostrich, etc.), etc. In the present invention, the subject may be healthy or may be suffering from some disease, and may include, for example, an individual with an increased amount of active oxygen or an individual expected to have an increased amount of active oxygen.

[0068] In this specification, "subject information" refers to various information related to the characteristics and condition of a subject. For example, when the subject is a human individual, information includes age, weight, sex, general health condition, presence or absence of disease, progression or severity of disease, drug sensitivity, presence or absence of concomitant drugs, and resistance to treatment.

[0069] (2) Solvent The pharmaceutical composition of the present invention may contain a pharma- ceutically acceptable solvent as necessary. The term "pharma-ceutically acceptable solvent" refers to a solvent commonly used in the field of formulation technology. Examples of the solvent include water or an aqueous solution, or an organic solvent. Examples of the aqueous solution include physiological saline, an isotonic solution containing glucose or other auxiliary agents, a phosphate buffer, and a sodium acetate buffer. Examples of the auxiliary agents include D-sorbitol, D-mannose, D-mannitol, sodium chloride, and other low-concentration nonionic surfactants, polyoxyethylene sorbitan fatty acid esters, etc. Examples of the organic solvent include ethanol.

[0070] (3) Carrier The pharmaceutical composition of the present invention may contain a pharma- ceutically acceptable carrier as necessary. The term "pharma-ceutically acceptable carrier" refers to additives commonly used in the field of formulation technology. Examples include excipients, binders, disintegrants, fillers, emulsifiers, flow additive regulators, lubricants, human serum albumin, etc.

[0071] Excipients include, for example, sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides, metallic salts, citric acid, tartaric acid, glycine, polyethylene glycol, Pluronic®, kaolin, silicic acid, or combinations thereof.

[0072] Binders include, for example, starch paste using vegetable starch, pectin, xanthan gum, simple syrup, glucose solution, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, shellac, paraffin, polyvinylpyrrolidone, or combinations thereof.

[0073] Disintegrants include, for example, the above-mentioned starches, lactose, carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, laminaran powder, sodium bicarbonate, calcium carbonate, alginic acid or sodium alginate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearate monoglyceride, or salts thereof.

[0074] Examples of fillers include petrolatum, the aforementioned sugars and / or calcium phosphate.

[0075] Examples of the emulsifier include surfactants (for example, polyethylene glycol, poloxamer, glyceryl acetate, isostearamide, sorbitan fatty acid esters, glycerin fatty acid esters, sucrose fatty acid esters, and propylene glycol fatty acid esters).

[0076] Examples of flow regulators and lubricants include silicates, talc, stearates or polyethylene glycol.

[0077] Examples of pH adjusters include alkaline agents such as sodium hydroxide and potassium hydroxide, and acid agents such as citric acid, sodium citrate, glycolic acid, and ascorbic acid.

[0078] In addition to the above, if necessary, the composition may appropriately contain solubilizers, suspending agents, diluents, dispersing agents, surfactants, soothing agents, stabilizers, absorption promoters, bulking agents, moisturizing agents, humectants, adsorbents, flavorings, deodorants, disintegration inhibitors, coating agents, colorants, preservatives, antiseptics, antioxidants, fragrances, flavorings, sweeteners, buffers, isotonicity agents, and the like that are commonly used in pharmaceutical compositions.

[0079] Carriers are used to avoid or inhibit decomposition of the active ingredient by enzymes and the like in the subject's body, as well as to facilitate formulation and administration methods and maintain the dosage form and medicinal efficacy, and may be used appropriately as needed.

[0080] (4) Drug delivery system particles (DDS particles) The pharmaceutical composition of the present invention may contain DDS particles as necessary. DDS particles refer to particles that contain active ingredients or other carriers inside, deliver the contents, especially the active ingredients, to the target site without decomposing them, and control the drug distribution in the body in terms of time and quantity. Since the active ingredient of the pharmaceutical composition of the present invention is a peptide or nucleic acid, the use of DDS particles is also suitable for protecting the active ingredient from degradation by proteases and nucleases in the body after administration. Any type of DDS particle may be used. Examples include liposomes, polymeric micelles, and virus particles.

[0081] 2-2-2. Dosage form The dosage form of the pharmaceutical composition of the present invention is not particularly limited, as long as it is in a form that allows the active ingredient to be delivered to the target site without being inactivated in the subject's body.

[0082] The specific dosage form varies depending on the application method described below. The application method can be roughly divided into parenteral administration and oral administration, so a dosage form suitable for each administration method may be used.

[0083] For example, if the administration method is parenteral administration, the preferred dosage form is a liquid that can be administered directly to the target site or systemically via the circulatory system. A preferred example of a liquid is an injection. The injection can be formulated by appropriately combining the solvent, the excipient, emulsifier, suspending agent, surfactant, stabilizer, pH regulator, etc., and mixing them in a unit dose form required for generally accepted pharmaceutical practice.

[0084] If the method of administration is oral administration, preferred dosage forms include solid agents (including tablets, capsules, drops, and lozenges), granules, powders, powders, and liquid agents (including oral waters, emulsions, and syrups). If the agent is a solid agent, it can be made into a dosage form with a coating known in the art, such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multi-layer tablets, as necessary.

[0085] The specific shape and size of each of the above dosage forms are not particularly limited as long as they are within the range of dosage forms known in the art. The pharmaceutical composition of the present invention may be prepared according to a conventional method in the art.

[0086] 2-3. Application method The pharmaceutical composition of the present invention may be administered orally or parenterally. Generally, oral administration is systemic administration, while parenteral administration can be further divided into systemic administration and local administration. Local administration includes, for example, intramuscular administration, subcutaneous administration, tissue administration, and organ administration, and systemic administration of parenteral administration includes administration into the circulatory system, for example, intravenous administration (intravenous injection), intraarterial administration, and intralymphatic administration. When the pharmaceutical composition of the present invention is administered locally, it may be administered directly to the liver by injection or the like. When the pharmaceutical composition is administered systemically, it may be administered into the circulatory system, for example, by intravenous injection. The dosage may be an amount effective for the active ingredient to take effect. The effective amount is appropriately selected according to the information of the subject as described above.

[0087] The pharmaceutical composition of the present invention may also be used in combination with one or more other known antioxidants, such as vitamin C (ascorbic acid), vitamin E (tocopherol), coenzyme Q10, carotenoids, flavonoids, or combinations thereof.

[0088] 2-4. Target disease or condition The composition of the present invention can prevent or treat diseases or conditions that are known to be associated with an increase in the amount of reactive oxygen species.

[0089] As used herein, the term "prevention" refers to preventing the onset of a disease (herein, for example, osteoporosis, etc.) before it occurs.

[0090] As used herein, the term "treatment" refers to the cure or amelioration of a disease. Here, "amelioration" refers to the alleviation or elimination of symptoms associated with a disease, and / or the prevention or suppression of progression.

[0091] The composition of the present invention is particularly useful for prevention, since it can exert a continuous systemic effect at a low dose. In this case, the composition of the present invention is administered to a healthy individual or an individual expected to have an increase in the amount of active oxygen. The individual expected to have an increase in the amount of active oxygen includes an individual who does not have symptoms but has a factor that causes an increase in the amount of active oxygen. Such factors include any factor that has been pointed out as being capable of increasing the amount of active oxygen, and include, but are not limited to, lifestyle habits, genetic factors, mental factors, etc.

[0092] The disease or condition to be prevented or treated by the composition of the present invention is not particularly limited as long as it is a disease or condition known to increase the amount of reactive oxygen, and examples thereof include blood diseases, metabolic bone diseases, lifestyle-related diseases, inflammatory diseases, autoimmune diseases, degenerative diseases (Alzheimer's disease, amyotrophic lateral sclerosis, Lou Gehrig's disease, etc.), cancer, etc.

[0093] Specific examples of blood diseases include blood clot formation, hyperlipidemia, uremia, diabetes, hypertension, fatty liver disease, alcoholic liver disease, kidney disease (e.g., renal failure such as chronic renal failure), diabetic kidney disease, polycystic kidney disease, heart failure, leukocytosis, neutropenia and leukocytosis, myeloid and lymphocytic leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, aplastic anemia, paroxysmal nocturnal hemoglobinuria, malignant lymphoma, and multiple myeloma.

[0094] Specific metabolic bone diseases or conditions include, for example, osteoporosis, osteomalacia, rickets, osteopetrosis, gonadal dysfunction, androgen suppression, vitamin D deficiency, secondary hyperparathyroidism, osteochondritis disease, osteochondroma, osteitis deformans, osteoarthritis, fibrous dysplasia, osteitis fibrosa cystic, symphysis pubis, sclerosing osteitis, osteogenesis imperfecta, osteomyelitis, osteopenia, osteonecrosis, bone atrophy, osteophytes, Paget's disease, hypercalcemia, neoplastic destruction of bone, fractures, decreased bone mass, cancer-related bone resorption diseases, osteolysis, osteoarthritis, rheumatoid arthritis, nutritional deficiencies, anorexia nervosa, and the like.

[0095] When the composition of the present invention is used for treating metabolic bone diseases, the apatite orientation of bone and / or the mechanical properties of bone (e.g., elastic modulus such as storage modulus) are improved. Preferably, the apatite orientation is improved without changing bone density or affecting the function of osteoclasts or osteoblasts.

[0096] In this specification, the term "apatite orientation" refers to the orientation in the c-axis direction (film thickness direction) of a crystal structure constituted by collagen and hydroxyapatite.

[0097] The composition of the present invention can be used for metabolic bone diseases accompanied by a decrease in apatite orientation of bone. The degree of decrease is not particularly limited, but for example, the composition can be used for metabolic bone diseases in which apatite orientation is decreased to 90% or less, 85% or less, 84.5% or less, 84% or less, 83% or less, 82% or less, 81% or less, 80% or less, 79% or less, 78% or less, 77% or less, 76% or less, 75% or less, 74% or less, 73% or less, 72% or less, 71% or less, or 70% or less compared to healthy individuals of the same species.

[0098] The composition of the present invention can be used for metabolic bone diseases accompanied by a decrease in bone elastic modulus, particularly storage elastic modulus.The degree of decrease is not particularly limited, but for example, metabolic bone diseases in which the storage elastic modulus is decreased to 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 54% or less, or 53.5% or less compared to healthy individuals of the same species can be used for the purpose.The storage elastic modulus can be measured as Young's modulus.

[0099] The composition of the present invention can be used for both metabolic bone diseases accompanied by a decrease in bone density and metabolic bone diseases not accompanied by a decrease in bone density. When a decrease in bone density is accompanied, the degree of decrease is not particularly limited. For example, metabolic bone diseases in which the bone density is decreased to less than 90% compared to healthy individuals of the same species are included. When a decrease in bone density is not accompanied, the bone density may be, for example, 90% or more compared to healthy individuals of the same species, and includes diseases exhibiting a bone density of 90.5% or more, 91% or more, 91.4% or more, 91.5% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 97.5% or more, 97.8% or more, 97.9% or more, 98% or more, or 99% or more. Bone density can be measured using known methods such as DXA, ultrasound, MD, and X-ray. As used herein, the term "inflammatory disease" refers to a disease that is accompanied by persistent or transient inflammation and whose symptoms can be improved by reducing the inflammation. Inflammatory diseases as used herein include both chronic inflammatory diseases and acute inflammatory diseases.

[0100] Specific examples of inflammatory diseases include allergic inflammatory diseases such as hay fever and delayed-type allergies; neuroinflammatory diseases such as diabetic neuropathy, dementia (Alzheimer's type, etc.), and multiple sclerosis; cancers caused by chronic inflammation such as colon cancer, lung cancer, bladder cancer, skin cancer, esophageal cancer, and liver cancer; inflammatory diseases involving macrophages such as hepatitis (alcoholic hepatitis, non-alcoholic hepatitis, etc.), asthma, systemic lupus erythematosus, Crohn's disease, and arthritis (chronic rheumatoid arthritis, etc.); and other inflammatory diseases such as arteriosclerosis, gastric ulcer, nephritis (glomerulonephritis, IgA nephropathy, diabetic nephropathy, etc.), periodontal disease (gingivitis, peridotitis, etc.), disorders due to kidney transplantation, acute myocardial infarction, diabetes, reflux esophagitis, cholangitis, celiac disease, vasculitis, and atherosclerosis.

[0101] The target disease or condition may be, for example, a disease associated with ectopic calcification. Specifically, for example, vascular calcification (e.g., vascular calcification in dialysis patients, arteriosclerosis patients, etc.), calciphylaxis, diabetic vasculopathy, soft tissue calcification, ectopic ossification, rheumatism, osteoarthritis, fibrodysplasia ossificans progressiva, cancer, cancer metastasis, hypercalcemia, scleroderma, dermatomyositis, calcific tendonitis, calcific bursitis, focal calcification, generalized calcification, ossification of the posterior longitudinal ligament of the cervical spine, ossification of the spinal ligament, hyperparathyroidism, vitamin D metabolic disorders, vitamin D insufficiency, and the like. These include poisoning, arteriosclerosis (e.g., Mönckeberg arteriosclerosis, etc.), atherosclerosis, arteriosclerosis, hypertensive arteriosclerosis, Mönckeberg arteriosclerosis, heart valve stenosis, blood clot formation, uremia, diabetes, hypertension, Werner's syndrome, pseudoxanthoma elasticum, angina pectoris, myocardial infarction, myocardial disorder, heart failure, cardiac conduction disorder, cerebral infarction, metastatic calcification, tartar formation, periodontal disease, bone and joint pain, bone deformation, fractures, muscle pain, wounds, inflammation, ischemic skin ulcers, urinary tract stones, kidney stones, renal failure, chronic renal failure, etc.

[0102] 3.Food and beverages 3-1. Overview The third aspect of the present invention is a food or drink. The food or drink of the present invention contains the antioxidant of the first aspect as an active ingredient. The food or drink of the present invention can exert an antioxidant effect in calcified tissue, blood, tissue fluid, or lymphatic fluid.

[0103] 3-2.Configuration The food and drink of the present invention contains the antioxidant of the first aspect. As used herein, the term "food and drink" is a general term referring to beverages, foods, and feeds.

[0104] Examples of beverages include water (including purified water, mineral water, and deep sea water), tea beverages (including green tea, oolong tea, and black tea), coffee, coffee beverages, milk (including raw milk and processed milk), dairy beverages, lactic acid bacteria beverages, juice, soft drinks (including carbonated beverages, fruit juice beverages, powdered drinks, and sports drinks), jelly beverages, cocoa beverages, brewed alcohol (including beer, sake, yellow wine, wine, and cider), distilled alcohol (including whiskey, brandy, vodka, rum, tequila, shochu, baijiu, and gin), and mixed alcohol (including liqueur, plum wine, and vermouth).

[0105] The food includes general foods (especially processed foods) and foods for specified health uses. Processed foods include, for example, bread, cooked rice, noodles, pasta, mayonnaise, shortening, custard cream, dressings, milk, yogurt, soup, miso soup, tofu, spreads (butter, jam, furikake, margarine, etc.), sauces, soy sauce, oil, and sweets (e.g., cookies, chocolate, candy, cake, ice cream, chewing gum), etc.

[0106] Examples of feed include feed for farmed fish and shellfish, feed for livestock, feed for ornamental animals, and pet food.

[0107] The food and drink of the present invention is added with the antioxidant according to the first embodiment during or after production. The method for producing the food and drink of this embodiment is not particularly limited. For example, the food and drink may be produced according to a conventional method by blending other food ingredients, various nutrients, various vitamins, minerals, amino acids, various oils and fats, and various additives (e.g., taste components, sweeteners, acidulants such as organic acids, surfactants, pH adjusters, stabilizers, antioxidants, colorants, flavors), etc., used in the production process of the food and drink. The food of the present invention can also be produced by adding the antioxidant according to the first embodiment to the food and drink after production.

[0108] The content of the antioxidant of the first embodiment in the food or drink varies depending on the form and purpose of the food or drink. For example, the content can be set so that the antioxidant is ingested at the dose exemplified in relation to the effective amount in the second embodiment.

[0109] The food and drink of the present invention may contain a pharma- ceutical or food hygienically acceptable solvent and / or carrier, as necessary.

[0110] Examples of pharmaceutically or food hygienically acceptable solvents include water, or other pharmaceutically or food hygienically acceptable solvents, such as aqueous solutions, oils, or organic solvents. As the aqueous solutions and organic solvents, those mentioned above as pharmaceutically acceptable solvents can be used. Examples of food hygienically acceptable oils include wheat germ oil, apricot oil, olive oil, camellia oil, evening primrose oil, aloe vera oil, rapeseed oil, palm oil, cottonseed oil, soybean oil, corn oil, safflower oil, sesame oil, linseed oil, castor oil, and other vegetable oils.

[0111] The food and drink of the present invention contains a pharma- ceutically or food hygienically acceptable carrier as necessary. Examples of the carrier include excipients, binders, fillers, emulsifiers, pH adjusters, hardening regulators, preservatives, and flow additive regulators. In addition to the above, solubilizers, diluents, dispersants, stabilizers, moisturizers, preservatives, isotonicity agents, etc. may also be appropriately contained as necessary. Specific examples of the carrier include the various carriers mentioned above as pharma-ceutically acceptable carriers.

[0112] The dosage form of the food or drink of the present invention is not particularly limited, and may be, for example, granules, powder, paste, gel, liquid, suspension, or the like.

[0113] 4. Calcium phosphate binder 4-1. Overview The fourth aspect of the present invention is a calcium phosphate binder. The calcium phosphate binder of this aspect contains a compound represented by formula (II) or a pharma- ceutically acceptable salt thereof as an active ingredient. The calcium phosphate binder of this aspect can deliver a desired substance to a site where calcium phosphate is present.

[0114] 4-2.Configuration The calcium phosphate binder of the present invention contains a compound represented by formula (II) or a pharma- ceutically acceptable salt thereof as an essential component.

[0115] [ka] (In the formula, R2 represents a hydrocarbon group having a substituent.)

[0116] The hydrocarbon group and the substituent, and the pharma- ceutically acceptable salt are basically the same as those described in the first embodiment, so only the points different from the first embodiment will be described here.

[0117] The R2 moiety in formula (II) may be a hydrocarbon group having a substituent that has a detectable label and / or a pharmacological activity.

[0118] As used herein, the term "detectable label" refers to a substance that emits a signal that allows its presence to be detected. The type of label is not particularly limited. Examples of the label include luminescent labeling substances that emit light under specific conditions, such as fluorescent molecules and chemiluminescent substances, sound-emitting labeling substances that emit sound waves, such as photoacoustic probes, and radioactive labeling substances.

[0119] Specific examples of fluorescent molecules include fluorescent proteins, fluorescein and its derivatives, pyrene and its derivatives, quantum dots, etc. Examples of chemiluminescent substances include enzymes such as peroxidase (HRP) and alkaline phosphatase (ALP), etc. Examples of radioactive labeling substances include 14 C. 3 H, 125 Examples of the photoacoustic effect probe include a reagent containing I and the like. The photoacoustic effect refers to a phenomenon in which adiabatic expansion accompanying light absorption generates a thermoelastic wave, and this thermoelastic wave can be detected as an acoustic wave. Examples of the photoacoustic effect probe include indocyanine green or a derivative thereof, a curcumin derivative, or a choline derivative. When the light absorption characteristics of the label used are known, for example, a luminescent labeling substance can be detected based on the photoacoustic effect without using a label for the photoacoustic effect.

[0120] "Pharmacological action" refers to an effect that brings about quantitative and / or qualitative changes in biological molecules such as proteins, DNA, and RNA. As a result of the physiological effect, for example, changes occur in the functions and properties of living organisms, organs, tissues, cells, etc. There are no particular limitations on the targets of changes due to physiological activity. For example, when the calcium phosphate binder of the present invention contains a hydrocarbon group having a substituent with a pharmacological action, biological functions such as metabolism, growth, reproduction, homeostasis, mental activity, and biological defense are changed.

[0121] The specific pharmacological action is not particularly limited, and examples thereof include an antioxidant action, an anti-inflammatory action, a blood circulation promoting action, a blood sugar lowering action, an antihypertensive action, a fibrin formation inhibiting action, a platelet aggregation inhibiting action, an antibacterial action, an antifungal action, a tumor suppressing action, and a cardiovascular protective action.

[0122] For example, existing bisphosphonic acid compounds or derivatives thereof can be used as the calcium phosphate binder of the present invention, specifically, for example, etidronate, clodronate, pamidronate, alendronate, risedronate, minodronate, ibandronate, incadronate, zoledronate, tiludronate, and the compound of the above-mentioned formula (I) (e.g., [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP)). EXAMPLES

[0123] Example 1: Analysis of the effect of low concentrations of [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) on bone (the purpose) We administered [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) at a concentration insufficient to regulate osteoclasts to examine its effect on bone in rats.

[0124] (method) 1. Rat Model Since it is known that bone metabolic abnormalities occur in chronic kidney disease, a chronic kidney disease model was used as a model of metabolic bone disease. Rats fed a high-adenine diet were used as the chronic kidney disease model. Eight-week-old wild-type male Sprague-Dawley rats obtained from Japan SLC were used.

[0125] After being kept for one week, the rats were divided into four groups of six each (week 0). The control group continued to be fed with normal chow, while the other three groups continued to be fed with a high-adenine diet (Sigma-Aldrich) for seven weeks.

[0126] Rats in each group received intraperitoneal injections of vehicle or [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) once a week from the third week. Saline was injected as the vehicle. The MPMBP treatment groups were injected with MPMBP at two concentrations, 0.6 mg / kg body weight and 1.2 mg / kg body weight. MPMBP was provided by Showa University.

[0127] In the seventh week, rats in each group were sacrificed 72 hours after administration of vehicle or MPMBP, and the subsequent analyses were carried out.

[0128] 2. Collection of bone samples The right femurs were collected from the sacrificed rats of each group and fixed in 70% ethanol.

[0129] 3. Measurement of bone density The bone mineral density of the fixed femur was measured by Dual Energy X-ray Absorptiometry (DEXA) using DCS-600-EX-III R (ALOKA). The femur was divided into four equal sections (between the vertical dashed lines in Fig. 1A) along the longitudinal central axis (horizontal dashed lines in Fig. 1A), and the bone mineral density of each section was measured in order from the side closest to the femoral head: the proximal section, the proximal diaphysis, the distal diaphysis, and the distal section.

[0130] 4. Measurement of bone mechanical properties In the fixed femur, Young's modulus was measured as the storage modulus in the section including the proximal and distal diaphysis using R-AXIS BQ (Rigaku Corporation).

[0131] 5. Trabecular Bone Morphometry The fixed femur was embedded in methyl methacrylate resin (Fujifilm Wako Pure Chemicals), and then sections (thickness: 5 μm) were prepared in the frontal direction using RM2255 (LEICA). The distal end of the prepared sections was stained with Villanueva Osteochrome Bone Stain (Polysciences). The stained sections were observed under an optical microscope (Nikon), and trabecular bone morphology was measured using OsteoMeasure (Shoshin EM). Parameters measured included unit bone mass, trabecular bone width, formation surface, resting surface, resorption surface, osteoblast surface, bone formation rate, and mineralization rate.

[0132] 6.Statistical analysis Statistical analysis was performed using SPSS with t-tests, with p<0.05 used as the significance level.

[0133] (result) The results are shown in Table 1 and Figures 1 and 2. The results of cancellous bone morphometry are shown in Table 1.

[0134] [Table 1]

[0135] No significant differences were observed between the control and high-adenine diet groups in bone structure indices (bone mass, trabecular width, trabecular number, and trabecular space). Similarly, no significant differences were observed between the control and high-adenine diet groups in osteoblast-related indices (osteoblast surface, osteoid surface). Osteoclast-related indices (osteoclast number, erosion surface) were significantly higher in the high-adenine diet group than in the control group. No effect was observed on these indices by administration of MPMBP. This was expected, as it was thought to be due to the low concentration of MPMBP administered. On the other hand, although the bone mineralization lag time was significantly higher in the high-adenine diet group than in the control group, there was no significant difference between the MPMBP administration group and the control group. This suggests that low concentrations of MPMBP normalize the bone formation reaction without the intervention of osteoclast function regulation as previously thought.

[0136] The fact that this concentration of MPMBP does not affect bone structure was also supported by the results of bone density measurements. As shown in Figure 1B-E, bone density was generally decreased in the high adenine diet group compared to the control group (Cont). However, administration of MPMBP had no effect on these indices. Administration of MPMBP had no effect on these indices.

[0137] On the other hand, as shown in Figure 2, the bone mechanical properties of the femoral shaft were generally decreased in the high adenine diet group (Adenine Diet) compared to the control group (Cont), but were significantly improved by MPMBP administration in a concentration-dependent manner. This result is consistent with the results of interface bone morphometry, which showed that bone formation was normalized without the mediation of osteoclast function.

[0138] Example 2. Analysis of the cause of the effect of low concentrations of MPMBP on bones (the purpose) To investigate the cause of the effect of MPMBP on bone at concentrations that are insufficient to regulate osteoclasts.

[0139] (method) 1. Rat Model The rat model used in Example 1 was used.

[0140] 2. Apatite orientation measurement In the femur fixed in Example 1, the orientation of the apatite crystals in the c-axis of the proximal part, the proximal diaphysis, the distal diaphysis, and the central part of the distal part (black circles in FIG. 3A) was measured using R-AXIS BQ (manufactured by Rigaku Corporation). The following parameters were used for the measurement: Collimator diameter: 300μm; X-ray exposure time: 180 sec.

[0141] 3. Sample Collection Right tibia and serum samples were collected from each group of sacrificed rats. The tibia samples were prepared as follows: after removal of the tibia, the bone marrow was washed out with phosphate-buffered saline, and the bone was quickly frozen in liquid nitrogen and crushed. After crushing, the bone was decalcified in 0.5 M EDTA / Tris buffer (pH 7.4) for 96 hours, and the decalcified bone fragments were reduced in NaBH4 / phosphate solution to be used as the tibia samples.

[0142] The weight of the tibia specimen was measured as the bone tissue mass. Serum samples were prepared by centrifuging the collected blood at 2000 G for 20 minutes and recovering the supernatant.

[0143] 4. Measurement of malondialdehyde content The amount of malondialdehyde, a lipid peroxidation product, was measured in the obtained tibia and serum samples using a malondialdehyde measurement kit (Northwest Life Science Specialties LLC). The amount of malondialdehyde in the tibia samples was standardized by the mass of the bone tissue, and the amount of malondialdehyde in the serum samples was standardized by the volume of the serum samples.

[0144] (result) The results are shown in Figures 3 to 5. As shown in Figures 3B-E, apatite orientation was significantly decreased in the high adenine diet group (Adenine Diet) compared to the control group (Cont), but the value improved in a dose-dependent manner with MPMBP. This suggests that MPMBP promotes the reorganization of the crystal structure in bone, improving apatite orientation, which leads to improved bone mechanical properties.

[0145] To further clarify the cause, the amount of malondialdehyde (a lipid peroxidation product) in the bones was measured. As a result, the oxidative stress increased by feeding a high-adenine diet was reduced by administration of MPMBP (Figure 4). Furthermore, the same effect was observed in the blood, showing the same changes as those in serum oxidative stress (Figure 5). Furthermore, blood indicators showed no effect of MPMBP on renal function (data not shown).

[0146] These results suggest that MPMBP reduces oxidative stress in blood and bone, creating an environment favorable for the reorganization of the crystal structure in bone. In addition, because the effect of MPMBP on bone is also seen in blood, it is suggested that MPMBP may have an antioxidant effect on the bone surface.

Claims

1. An antioxidant for binding to calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph, the antioxidant comprising a compound represented by the following formula (I) or a pharma- ceutical acceptable salt thereof: 【Chemistry 1】 (In the formula, R 1 represents a hydrocarbon group or a hydrocarbon group having a substituent.

2. The antioxidant according to claim 1 , wherein the calcified tissue is ectopic calcified tissue.

3. The antioxidant according to claim 2 , wherein the ectopic calcified tissue is vascular tissue.

4. A food or drink comprising the antioxidant according to any one of claims 1 to 3.

5. A pharmaceutical composition comprising the antioxidant according to any one of claims 1 to 3.

6. The pharmaceutical composition according to claim 5 for preventing or treating a blood disorder.

7. The pharmaceutical composition according to claim 6, wherein the blood disease is one or more diseases selected from the group consisting of blood clot formation, hyperlipidemia, uremia, diabetes and hypertension.

8. A composition for preventing or treating a metabolic bone disease, comprising the antioxidant according to any one of claims 1 to 3 in an amount such that the weekly dose to a subject weighing 60 kg is 31 µmol or less.

9. The composition of claim 8, wherein the metabolic bone disease is one or more diseases selected from the group consisting of osteoporosis, osteomalacia, rickets and osteopetrosis.

10. A calcium phosphate binder comprising a compound represented by the following formula (II) or a pharma- ceutically acceptable salt thereof: 【Chemistry 2】 (In the formula, R 2 represents a hydrocarbon group having a substituent.)

11. The calcium phosphate binder according to claim 10, wherein the hydrocarbon group having a substituent has a detectable label and / or a pharmacological action.

Citation Information

Patent Citations

  • Rear bumper structure made of resin

    JP1996026048A

  • Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient

    WO2010026701A1

  • JP2019、153